var data={"title":"Guaifenesin, dextromethorphan, and phenylephrine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Guaifenesin, dextromethorphan, and phenylephrine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/100102?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=guaifenesin-dextromethorphan-and-phenylephrine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Guaifenesin, dextromethorphan, and phenylephrine: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1698817\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aquanaz [OTC];</li>\n      <li>Deconex DMX [OTC];</li>\n      <li>Duravent DM [OTC];</li>\n      <li>Endacon [OTC] [DSC];</li>\n      <li>GoodSense Children's Mucus Relief Multi-Symptom Cold [OTC];</li>\n      <li>GoodSense Mucus Relief Severe Congestion &amp; Cough [OTC];</li>\n      <li>GoodSense Tussin CF [OTC];</li>\n      <li>Maxiphen DM [DSC];</li>\n      <li>Mucinex Children's Congestion &amp; Cough [OTC];</li>\n      <li>Mucinex Children&rsquo;s Multi-Symptom Cold [OTC];</li>\n      <li>Mucinex Fast-Max Severe Congestion &amp; Cough [OTC];</li>\n      <li>NeoTuss-D [OTC];</li>\n      <li>Nivanex DMX [OTC];</li>\n      <li>Relhist DMX [OTC] [DSC];</li>\n      <li>Robafen CF Cough &amp; Cold [OTC] [DSC];</li>\n      <li>Robitussin Children's Cough &amp; Cold CF [OTC];</li>\n      <li>Robitussin Peak Cold Maximum Strength Multi-Symptom Cold [OTC];</li>\n      <li>Robitussin Peak Cold Multi-Symptom Cold [OTC];</li>\n      <li>Tusicof [OTC];</li>\n      <li>Tussin CF Cough &amp; Cold [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699136\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antitussive;</li>\n      <li>\n        Decongestant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699161\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Also refer to specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cough/decongestant:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liquid (Robitussin Peak Cold Multi-Symptom Cold): Guaifenesin 200 mg, dextromethorphan 20 mg, and phenylephrine 10 mg (10 mL) every 4 hours; maximum: 60 mL/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Syrup (Tusicof): Guaifenesin 400 mg, dextromethorphan 20 mg, and phenylephrine 10 mg (5 mL) every 4 hours; maximum: 30 mL/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (Deconex DMX): Guaifenesin 385 mg, dextromethorphan 17.5 mg, and phenylephrine 10 mg (1 tablet) every 4 hours; maximum: 6 tablets/24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699160\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Also refer to specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cough/decongestant:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 11 years (Deconex DMX): Guaifenesin 192.5 mg, dextromethorphan 8.75 mg, and phenylephrine 5 mg (1/2 tablet) every 4 hours; maximum: 3 tablets/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liquid (OTC labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 5 years (Mucinex Children's Congestion &amp; Cough): Oral: Guaifenesin 100 mg, dextromethorphan 5 mg, and phenylephrine 2.5 mg (5 mL) every 4 hours, not to exceed 30 mL/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 11 years (Mucinex Children's Congestion &amp; Cough): Oral: Guaifenesin 200 mg, dextromethorphan 10 mg, and phenylephrine 5 mg (10 mL) every 4 hours, not to exceed 60 mL/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents (Robitussin Peak Cold Multi-Symptom Cold): Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699162\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50148393\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50148394\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699168\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Children's Mucus Relief Multi-Symptom Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [gluten free; contains edetate disodium, propylene glycol, sodium benzoate, and sodium 3 mg/5 mL; very berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Mucus Relief Severe Congestion &amp; Cough: Guaifenesin 100 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (177 mL) [contains edetate disodium, propylene glycol, sodium benzoate, and sodium 4 mg/5 mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Tussin CF: Guaifenesin 100 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 237 mL) [gluten free; contains propylene glycol, sodium benzoate, and sodium 2.5 mg/5 mL; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex Children&rsquo;s Multi-Symptom Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL, 201 mL) [ethanol free; contains propylene glycol, sodium benzoate, and sodium 3 mg/5 mL; very berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex Children's Congestion &amp; Cough: Guaifenesin 100 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (201 mL) [contains propylene glycol, sodium benzoate; berrylicious flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex Fast-Max Severe Congestion &amp; Cough: Guaifenesin 100 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (180 mL, 266 mL) [contains propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NeoTuss-D: Guaifenesin 200 mg, dextromethorphan hydrobromide 30 mg, and phenylephrine hydrochloride 7.5 mg per 5 mL (474 mL) [dye free, ethanol free, sugar free; contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Robitussin Children's Cough &amp; Cold CF: Guaifenesin 50 mg, dextromethorphan hydrobromide 5 mg, and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 3 mg/5 mL, and sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Robitussin Peak Cold Maximum Strength Multi-Symptom Cold: Guaifenesin 200 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 237 mL) [contains menthol, propylene glycol, sodium 3 mg/5 mL, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Robitussin Peak Cold Multi-Symptom Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 237 mL) [contains menthol, propylene glycol, sodium 3 mg/5 mL, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tusicof: Guaifenesin 400 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per 5 mL (120 mL, 474 mL) [alcohol free, sugar free, dye free; contains menthol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tussin CF Cough &amp; Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 237 mL) [ethanol free; contains propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Syrup, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endacon: Guaifenesin 100 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg per 5 mL (473 mL [DSC]) [ethanol free, sugar free; contains benzoic acid, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Robafen CF Cough &amp; Cold: Guaifenesin 100 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg per 5 mL (118 mL [DSC]) [ethanol free; contains menthol, propylene glycol and sodium benzoate; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aquanaz: Guaifenesin 400 mg, dextromethorphan hydrobromide 15 mg, and phenylephrine hydrochloride 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Deconex DMX: Guaifenesin 385 mg, dextromethorphan hydrobromide 17.5 mg, and phenylephrine hydrochloride 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duravent DM: Guaifenesin 395 mg, dextromethorphan hydrobromide 15 mg, and phenylephrine hydrochloride 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maxiphen DM: Guaifenesin 400 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex Fast-Max Severe Congestion &amp; Cough: Guaifenesin 200 mg, dextromethorphan hydrobromide 10 mg, and phenylephrine hydrochloride 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nivanex DMX: Guaifenesin 380 mg, dextromethorphan hydrobromide 15 mg, and phenylephrine hydrochloride 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relhist DMX: Guaifenesin 380 mg, dextromethorphan hydrobromide 15 mg, and phenylephrine hydrochloride 10 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tusicof: Guaifenesin 400 mg, dextromethorphan hydrobromide 20 mg, and phenylephrine hydrochloride 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1698818\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50148395\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Only use dosing cup provided with liquid formulations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699137\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cough/decongestant:</b> Temporary control of nasal congestion and cough due to minor throat and bronchial irritation associated with the common cold, hay fever, or other upper respiratory allergies; help loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive; reduces swelling of nasal passages</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699146\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\"> Frequency not defined. The following adverse events have been reported with the combination product. Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Circulatory shock, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, central nervous system depression, convulsions, dizziness, drowsiness, excitability, fear, hallucination, headache, insomnia, irritability, nervousness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699142\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699143\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated, sedated and/or patients confined to the supine position.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2D6 poor metabolizers: Dextromethorphan is metabolized by hepatic CYP2D6. Poor metabolizers of CYP2D6 may have exaggerated or prolonged effects of dextromethorphan. Increased risk may be seen with concomitant use of potent CYP2D6 inhibitors; use with caution (Abduljalil 2010; Jurica 2012; Sager 2014; Zhou 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in atopic children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing. Re-evaluate if cough persists &gt;7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days, or are accompanied by fever, rash, or persistent headache.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699150\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699149\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8807&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: May increase the serum concentration of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Phenylephrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Phenylephrine (Systemic) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: May increase the serum concentration of Dextromethorphan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). Management: Monitor patients closely for increased side effects of phenylephrine if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.<b> Exceptions: </b>FluvoxaMINE.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Dextromethorphan. Management: Consider avoiding dextromethorphan in patients taking tipranavir. If combined, monitor closely for increased dextromethorphan effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699139\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699141\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699155\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1699157\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322881\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Biotuss Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-50 mg/mL (60 mL): $4.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Broncotron PED Drops Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-100 mg/mL (60 mL): $14.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Broncotron PED Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-15-350 mg/5 mL (118 mL): $14.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Desgen DM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-10-100 mg/5 mL (474 mL): $14.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Desgen Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-50 mg/mL (30 mL): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Exactuss Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-28-388 mg/5 mL (473 mL): $11.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (G-Tron Ped Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-15-350 mg/5 mL (474 mL): $24.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (G-Tron Pediatric Drops Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-100 mg/mL (30 mL): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (G-Tusicof Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-20-400 mg/5 mL (474 mL): $11.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Giltuss Cough &amp; Cold Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5-150-5 mg/2.5 mL (118 mL): $7.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Giltuss Cough &amp; Cold Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-15-300 mg/5 mL (118 mL): $7.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-29-390 mg/5 mL (118 mL): $7.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Giltuss Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-28-388 mg/5 mL (237 mL): $26.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Giltuss Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-7.5-88 mg/mL (60 mL): $26.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Mucinex Cold Childrens Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-100 mg/5 mL (118 mL): $8.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Mucinex Congest &amp; Cough Child Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-100 mg/5 mL (201 mL): $11.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Mucinex Fast-Max Congest Cough Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-100 mg/5 mL (180 mL): $12.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-20-400 mg/20 mL (180 mL): $11.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (NeoTuss-D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5-30-200 mg/5 mL (474 mL): $56.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Nortuss-DE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-50 mg/mL (30 mL): $10.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Robitussin Child Cough/Cold CF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-50 mg/5 mL (118 mL): $5.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Robitussin Multi-Symptom Max Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-10-200 mg/5 mL (118 mL): $6.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Robitussin Peak Cold Multi-Sym Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-10-100 mg/5 mL (118 mL): $5.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Robitussin To Go Cough/Cold CF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-10-100 mg/5 mL (10 mL): $0.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tusicof Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-20-400 mg/5 mL (120 mL): $13.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tussi-Pres Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-10-200 mg/5 mL (10 mL): $1.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tussi-Pres Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-5-75 mg/5 mL (120 mL): $9.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tusslin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-28-388 mg/5 mL (474 mL): $7.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tusslin Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-7.5-88 mg/mL (30 mL): $4.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Deconex DMX Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-17.5-385 mg (90): $67.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Duravent DM Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-15-395 mg (60): $55.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Exactuss TR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-28-388 mg (100): $65.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Giltuss Cough &amp; Cold Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-28-388 mg (20): $8.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Giltuss TR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-28-388 mg (100): $119.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mucinex Fast-Max Congest Cough Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-10-200 mg (20): $11.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nivanex DMX Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-15-380 mg (60): $35.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tusicof Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-20-400 mg (60): $27.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abduljalil K, Frank D, Gaedigk A, et al. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. <i>Clin Pharmacol Ther</i>. 2010;88(5):643-651. doi: 10.1038/clpt.2010.137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guaifenesin-dextromethorphan-and-phenylephrine-drug-information/abstract-text/20881950/pubmed\" target=\"_blank\" id=\"20881950\">20881950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Children's Mucinex Congestion &amp; Cough (dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride) [prescribing information]. Parsippany, NJ: Reckitt Benckiser LLC; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deconex DMX (dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride) [prescribing information]. Huntsville, AL: Poly Pharmaceuticals; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jurica J, Bartecek R, Zourkova A, et al. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. <i>J Clin Pharm Ther</i>. 2012;37(4):486-490. doi:10.1111/j.1365-2710.2012.01333.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guaifenesin-dextromethorphan-and-phenylephrine-drug-information/abstract-text/22548589/pubmed\" target=\"_blank\" id=\"22548589\">22548589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robitussin Peak Cold Multi-Symptom Cold (dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride) [prescribing information]. Available at: https://www.robitussin.com/products/multi-symptom-cold-cf. Accessed March 23, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sager JE, Lutz JD, Foti RS, et al. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. <i>Clin Pharmacol Ther</i>. 2014;95(6):653-662. doi: 10.1038/clpt.2014.50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guaifenesin-dextromethorphan-and-phenylephrine-drug-information/abstract-text/24569517/pubmed\" target=\"_blank\" id=\"24569517\">24569517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taverner D, Latte J. Nasal decongestants for the common cold. <i>Cochrane Database Syst Rev</i>. 2007;(1):CD001953.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guaifenesin-dextromethorphan-and-phenylephrine-drug-information/abstract-text/17253470/pubmed\" target=\"_blank\" id=\"17253470\">17253470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tusicof (dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride) [prescribing information]. San Juan, PR: Kramer Novis; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. <i>Clin Pharmacokinet</i>. 2009;48(12):761-804. doi:10.2165/11318070.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guaifenesin-dextromethorphan-and-phenylephrine-drug-information/abstract-text/19902987/pubmed\" target=\"_blank\" id=\"19902987\">19902987</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8807 Version 133.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F1698817\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F1699136\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F1699161\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1699160\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F1699162\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50148393\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50148394\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F1699168\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F1698818\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50148395\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1699137\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F1699146\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F1699142\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F1699143\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F1699150\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F1699149\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1699139\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F1699141\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F1699155\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F1699157\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322881\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8807|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=guaifenesin-dextromethorphan-and-phenylephrine-patient-drug-information\" class=\"drug drug_patient\">Guaifenesin, dextromethorphan, and phenylephrine: Patient drug information \t</a></li></ul></div></div>","javascript":null}